Laboratorios Farmaceuticos ROVI

Laboratorios Farmaceuticos ROVI FCF/Debt

The Free Cash Flow to Debt Ratio of Laboratorios Farmaceuticos ROVI (ROVI.MC) as of Oct 21, 2026 is 106.91 %. In the previous year, Free Cash Flow to Debt Ratio was 66.48 % — a change of 60.82% (higher).

FCF/Debt

106.91 %

YoY

60.82%

Last updated:

Free Cash Flow to Debt Ratio of Laboratorios Farmaceuticos ROVI is 2025 106.91 % . Free Cash Flow to Debt Ratio of Laboratorios Farmaceuticos ROVI was 2024 66.48 % . It decreases by 60.82% higher compared to the previous year.

The Laboratorios Farmaceuticos ROVI FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2018
-52.38 EUR
Jan 1, 2019
-58.54 EUR
Jan 1, 2020
9.77 EUR
Jan 1, 2021
148.34 EUR
Jan 1, 2022
258.14 EUR
Jan 1, 2023
88.74 EUR
Jan 1, 2024
66.48 EUR
Jan 1, 2025
106.91 EUR
The Laboratorios Farmaceuticos ROVI FCF/Debt history
YEARFCF/DebtYoY
106.91 %+60.82%
66.48 %-25.09%
88.74 %-65.62%
258.14 %+74.02%
148.34 %+1,418.02%
9.77 %-116.69%
-58.54 %+11.75%
-52.38 %+1,088.94%
-4.41 %-105.42%
81.23 %+266.11%
22.19 %-492.55%
-5.65 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Laboratorios Farmaceuticos ROVI Stock analysis

What does Laboratorios Farmaceuticos ROVI do? Laboratorios Farmaceuticos ROVI SA is a Spanish pharmaceutical company that was founded in 1946 by Salvador and Ignacio Ruiz-Salmones. The company is headquartered in Madrid and employs over 1,000 employees. ROVI manufactures a variety of pharmaceutical products and offers services in various areas. The company specializes in the development and manufacturing of specialty preparations in the fields of oncology, hematology, endocrinology, and gastroenterology. The company operates in three business areas: specialty pharmaceuticals, contrast agents, and active ingredients for the industry. The specialty pharmaceuticals business area includes medications for various applications, such as the treatment of cancer, blood disorders, endocrine disorders, gastroenterological disorders, and central nervous system disorders. The contrast agents division produces products for radiology and diagnostics. The products are used in various medical fields, from cardiology to gastroenterology. In the active ingredients for the industry business area, ROVI manufactures active ingredients for other pharmaceutical companies. ROVI specializes in the production of specialty products and relies on collaborations with other companies. The company has strategic partnerships with many companies such as GlaxoSmithKline, Pfizer, Sanofi-Aventis, and Zeltia. This also includes some research collaborations to develop and market products together. The company is also dedicated to the development of biosimilars, which allow for the offering of biologic drugs at a lower price. Biosimilars are copies of biopharmaceuticals that are usually very expensive due to the complex manufacturing process and high development costs. ROVI is also a major producer of vaccines that are distributed worldwide. ROVI has followed a solid growth trajectory in recent years. The company has been able to consistently increase its revenue and profit and is now a major player in the pharmaceutical industry. The company also operates a strong research and development department that constantly develops new products and technologies to improve patient care. In summary, Laboratorios Farmaceuticos ROVI SA is a leading pharmaceutical company specializing in the manufacturing of specialty products. With its subsidiaries in Europe and the USA, ROVI has an international presence and has made a name for itself through its expertise in the development and manufacturing of innovative pharmaceutical products. Laboratorios Farmaceuticos ROVI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Laboratorios Farmaceuticos ROVI stock

Free Cash Flow to Debt Ratio of Laboratorios Farmaceuticos ROVI is 106.91 % in 2025.

Free Cash Flow to Debt Ratio of Laboratorios Farmaceuticos ROVI changed from 66.48 % to 106.91 %, representing a 60.82% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Laboratorios Farmaceuticos ROVI since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Laboratorios Farmaceuticos ROVI with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Laboratorios Farmaceuticos ROVI

All Key Metrics — Laboratorios Farmaceuticos ROVI